Pharma channel feed

Dis­counts for weight loss drugs are es­ti­mat­ed at more than half, fu­el­ing ques­tions about price, PBMs and cov­er­age

Last year

Pfiz­er and BioN­Tech re­solve mR­NA patent law­suit filed by Pro­mo­some

Last year
Law

Ar­cutis wins la­bel ex­pan­sion for younger use of pso­ri­a­sis cream Zo­ryve

Last year
FDA+

Mi­rati is once again the cen­ter of buy­out ru­mors, and a ri­val's ad­comm pro­vides a boost

Last year

Am­gen clos­es $28B Hori­zon ac­qui­si­tion a month af­ter FTC bat­tle end­ed

Last year
Deals

Apel­lis’ Syfovre on the come­back trail from vas­culi­tis wor­ries af­ter $74M in ini­tial Q3 sales

Last year

HHS an­nounces move to com­mer­cial dis­tri­b­u­tion for Mer­ck­'s an­tivi­ral Lagevrio

Last year

Rea­gan-Udall Foun­da­tion lays out meth­ods for FDA to com­bat mis­in­for­ma­tion

Last year
FDA+

Newest FDA-ap­proved opi­oid use dis­or­der drug en­ters the mar­ket with flex­i­ble dos­ing

Last year
Marketing

Im­pel con­sid­ers strate­gic al­ter­na­tives, takes out $2.5M loan to con­tin­ue op­er­at­ing

Last year
People

Patent ap­peal board takes up Ozem­pic chal­lenge

Last year

Slew of phar­ma in­dus­try play­ers form coali­tion to push back against an­titrust re­form

Last year
FDA+

San­doz shares dip on first day of Swiss list­ing af­ter No­var­tis spin­off

Last year

Lil­ly's di­a­betes and obe­si­ty leader to re­tire in broad­er lead­er­ship shuf­fle as CSO Dan Skovron­sky takes on im­munol­o­gy role

Last year
People

We­govy, Ozem­pic ex­clu­siv­i­ty chal­lenges de­nied by US patent ap­peal board

Last year

FDA clears No­vavax’s fall boost­er for Covid-19, weeks af­ter mR­NA vac­cine boost­ers 

Last year
FDA+
Coronavirus

Mar­ket­ingRx roundup: Phar­mas nab ‘green­est’ awards; Gilead spon­sors ESG ex­ec­u­tive con­fer­ence

Last year
Marketing

Bris­tol My­ers notch­es di­ver­si­ty gains af­ter re­vamp­ing its clin­i­cal tri­al lo­ca­tion strat­e­gy

Last year
Marketing

Ex­sci­en­tia ends can­cer study as it fo­cus­es on oth­er tri­als of AI-dri­ven drug can­di­dates

Last year
R&D
AI

Eli Lil­ly to buy ra­dio­phar­ma com­pa­ny Point Bio­phar­ma for $1.4B as PhI­II read­out looms

Last year
Deals

As­traZeneca pays out $425M to set­tle lit­i­ga­tion over Prilosec and Nex­i­um but ad­mits no wrong­do­ing

Last year
Law

Take­da to pull lung can­cer drug Exkiv­i­ty world­wide af­ter con­fir­ma­to­ry tri­al dis­ap­point­ment

Last year

Hori­zon de­buts lat­est thy­roid eye dis­ease TV com­mer­cials as Am­gen merg­er nears

Last year
Marketing

No­vo Nordisk se­cures FDA ap­proval of RNAi ther­a­py from $3.3B Dicer­na takeover

Last year
FDA+
First page Previous page 979899100101102103 Next page Last page
A service from the Financial Times